Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arotinolol Hydrochloride Tablets Bioequivalence Study in Healthy Subjects
CTR20210372Phase 4Completed
- Sponsor
- Zhongjian Kangqiao Pharmaceutical Group Co., Ltd.
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of arotinolol in essential hypertension, angina pectoris, tachyarrhythmia, essential tremor (ET), sponsored by Zhongjian Kangqiao Pharmaceutical Group Co., Ltd.. Started Mar 2021; status: completed.
02
Drugs
arotinolol
03
Conditions
essential hypertensionangina pectoristachyarrhythmiaessential tremor (ET)
Beyond the preview
Go deeper on CTR20210372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210372.